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OBJECTIVE: This study aims to analyze pharmacological interactions among drugs taken by elderly patients and their
age and gender differences in a population from Porto Alegre, Brazil.
METHODS: We retrospectively analyzed the database provided by the Institute of Geriatric and Gerontology, Porto
Alegre, Brazil. The database was composed of 438 elderly and includes information about the patients’ disease,
therapy regimens, utilized drugs. All drugs reported by the elderly patients were classified using the Anatomical
Therapeutic and Chemical Classification System. The drug-drug interactions and their severity were assessed using
the MicromedexH Healthcare Series.
RESULTS: Of the 438 elderly patients in the data base, 376 (85.8%) used pharmacotherapy, 274 were female, and
90.4% of females used drugs. The average number of drugs used by each individual younger than 80 years was
3.2¡2.6. Women younger than 80 years old used more drugs than men in the same age group whereas men older
than 80 years increased their use of drugs in relation to other age groups. Therefore, 32.6% of men and 49.2% of
women described at least one interaction, and 8.1% of men and 10.6% of women described four or more potential
drug-drug interactions. Two-thirds of drug-drug interactions were moderate in both genders, and most of them
involved angiotensin-converting enzyme inhibitor, non-steroidal anti-inflammatory, loop and thiazide diuretics,
and b-blockers.
CONCLUSION: Elderly patients should be closely monitored, based on drug class, gender, age group and nutritional
status.
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INTRODUCTION
Aging is the main risk factor for the development of
chronic diseases, and this phenomenon is increasing world-
wide.1 Although chronologic age is most often used to
define the population $65 years old in developed countries
and .60 years old in developing countries, the elderly are
considered a heterogeneous group, with individuals aging
at varying rates.2
The elderly are the predominant users of pharmaceuticals
in the population.3 Thus, aging of the population could be a
reason for an increased use of pharmaceutical products.
These patients often have multiple diseases, and so they
require multiple drugs. It is well documented that poly-
pharmacy has a greater potential to lead to drug interactions
and adverse events.4 Pharmacological interactions contri-
bute to the decreased in general health in the elderly,
leading to disability, reduced quality of life, raising the
number of hospital admissions, a longer duration of
hospital stays, a greater need for ambulatory services, and
increased healthcare costs.5
Physiological alterations in the body with age make the
elderly more susceptible to interactions. These processes
include a decrease of renal function and hepatic metabo-
lism, gastro-intestinal tract alterations, and nutritional status
deficiency.6 Therefore, body fat gains and muscle mass
losses are normally seen in the elderly population, and these
factors are also determinants of the intensity of drug
interactions.7
Considering the prevalent use of polypharmacy and the
health hazards due to drug-drug interaction in the elderly,
this study aims to analyze potential pharmacological
interactions among drugs taken by elderly patients and
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their age and gender differences in a population from Porto
Alegre, Brazil.
METHODS
This observational, cross-sectional study is part of an
epidemiological project (Multidimensional Study of Elderly
in Porto Alegre) that represents a partnership between the
Porto Alegre City Hall and the Instituto de Geriatria e
Gerontologia (IGG) - Pontifı´cia Universidade Cato´lica do
Rio Grande do Sul (PUCRS). The elderly interviewed were
randomly recruited, between January 2006 and May 2007,
by the University social service professionals, from different
socioeconomic groups as previously described by Faggiani
et al.8 To participate in this research study, the following
inclusion criteria were used: individuals were able-bodied
(to allow for travel to the interview site) and were older than
sixty years old. The elderly who refused to participate in the
study were excluded. The sample size for this study was in
accordance to the number of individuals estimated for each
neighborhood of Porto Alegre and was updated by the
Brazilian Institute of Geography and Statistics according to
an estimation of the population variation through 2005.9
The database generated from Multidimensional Study of
Elderly in Porto Alegre was used in the present study for
retrospective analysis. The database was constructed from a
previously validated pharmacotherapeutic questionnaire
that elderly filled out based on their memory and/or using
materials supplied to them, such as prescriptions and/or a
prescription label. The data were collected, and results were
kept in and the individual patient’s file, together with the
completed questionnaires.
For the present study, we retrospectively analyzed the
database provided by the IGG. To evaluate potential drug-
drug interactions (DDI), we considered the most frequently
interacting drug pairs in a computerized database10 of the
pharmacotherapy used in elderly individuals from Porto
Alegre-RS, Brazil. The database was composed of 438
elderly and includes information about the elderly general
disease and therapy regimens, the prescribed and utilized
drugs, the general pharmacological classes, of those drugs,
the number of drugs used, and the frequency of self-
medication (all drug administration, except those prescribed
by a physician).
The Anatomical Therapeutic and Chemical Classification
System (ATC)11 was used to classify the drugs that the elderly
reported using, and the analysis of the potential DDI
was performed according to Reis and Cassiani,12 using
the computer software MicromedexH Healthcare Series
(Thomson MicromedexTM, Greenwood Village, Co, USA).13
A severity rating scale employing the categories of ‘‘low’’
interaction (risk of adverse outcomes appears small), ‘‘mod-
erate’’ interaction (to avoid administration unless it is
determined that the benefit of co-administration outweighs
the risk to the elderly), and ‘‘severe’’ interaction (to avoid
administration of combination) was used to describe the
potential DDI. Furthermore, it has been provided an
association of the clinical consequences or adverse reac-
tions to drugs and the characterization of the interaction
mechanisms.
Polypharmacy was defined as the use of more than three
drugs that have the potential to cause drug interactions and
side effects.4 The questionnaires contained no information
about the timing of or beverage and/or food consumption
with the drug administration. For this reason, all type of
interactions we found in this study must be considered
‘‘potential interactions.’’
The Institutional Ethics Committee of PUCRS approved
this study (number 0502935), and all the study participants
signed consent forms.
The data were analyzed and tabulated using the
computer program SPSS v17.0, and the results were
presented as a percentage of the data set. Ninety-five
percent confidence intervals (95% CI) were utilized to show
differences in the elderly characteristics. Statistical analysis
was performed considering age groups ,80 and $80 years
old using a Student’s t test to compare the average between
the two groups and a Pearson’s Chi-Square test to identify
the severity of the interactions. Results were expressed as
mean¡sd, and a p-value ,0.05 was considered significant.
RESULTS
In this study, a population of elderly individuals
provided information on their use of all categories of drugs,
and this information was analyzed to determine potential
DDI within this population. Preliminarily, we evaluated
three age groups (60 to 69, 70 to 79, and $80 years old).
According to those results, we performed another statistical
analysis considering only two age groups: ,80 and $80
years old. In both analyses, we gathered information about
whether individuals used drugs (yes/no), the number of
drugs used per day (1 to 3, 4 to 6, and $7), the number of
interactions (0, 1, 2, 3, and $4), and the severity of the
interactions (low, moderate, and severe) (Table 1).
Use of pharmacotherapy
Of the 438 elderly individuals interviewed, 376 (85.8%)
used pharmacotherapy, and only 62 (14.2%) people older
than 60 years old did not use any drugs. Table 1 shows that
the majority of the population (90.4%) that used drugs was
female (N= 274). In this case, differences among age groups
were not significant. Women ,80 years old used more
drugs than men in the same age group (p,0.001); however,
in the population $80 years old, the differences between
genders were not significant. Men $80 years old tended to
increase their use of drugs in relation to other age groups of
the same gender (p= 0.057). Regarding the number of drugs
used by the elderly, the majority of this population used
from one to three drugs (3.20¡2.61), and the average
number of drugs used by women 79 years old or younger
(3.58¡2.74) was higher than the average used by men
(2.20¡2.02) in the same age group (p,0.001). However,
among men, the number of drugs used increased with age
(4.53¡3.23) (p= 0.010) (Table 1).
The majority of women (36.9%) used five or more drugs
active principles, whereas the majority of men (41.2%) used
between one and two drugs active principles. Among men,
the number of drugs’ active principles used increased with
age (p= 0.012).
Potential drug-drug interactions
We found that the number of potential DDI increased in
parallel with the number of drugs used by the elderly. In
all age groups analyzed, 32.6% of men and 49.2% of
women described at least one interaction. Moreover, 8.1%
of men and 10.6% of women reported four or more
potential DDI. Among women, the DDI were more
Pharmacological interactions in the elderly
Venturini CD et al.
CLINICS 2011;66(11):1867-1872
1868
frequent in individuals younger than 80 years old
(p= 0.001), whereas men experienced more potential DDI
as age increased; most DDI in men occurred after age 80.
Regarding the intensity of drug interactions, two-thirds of
them were of moderate severity in both genders, and there
were no statistically significant differences among all age
groups analyzed.
Among those individuals who used drugs, there were 591
interactions reported. The 30 most frequent types of DDI are
shown in Table 2 (intensity and possible effects), most of
them involving angiotensin-converting enzyme inhibitors
(e.g., captopril, enalapril), non-steroidal anti-inflammatory
(NSAIDs) agents (e.g., aspirin, diclofenac, ibuprofen), loop
and thiazide diuretics (e.g., furosemide, hydrochlorothia-
zide), and b-adrenergic blockers (e.g., propranolol).
According to our data, cardiovascular system drugs were
the most prescribed drug class (62.3%). The second most
frequently used drugs were analgesic and anti-inflamma-
tory agents (34.6%), followed by central nervous system
drugs (20.8%). Unexpectedly, vitamin and mineral supple-
ments are used by 15.1% of the patients studied.
DISCUSSION
In this study, we examined an elderly population from
Porto Alegre, RS, Brazil, and analyzed drug consumption
and the potential DDI as well the intensity of DDI in both
genders and in several age groups of elderly patients. Other
studies reporting drug utilization by the elderly from
different countries have already been performed and have
shown a high incidence of polytherapy.14,15 Although there
are several published studies describing polypharmacy and
pharmacological interactions, such data on Brazilian
patients over 80 years old are lacking. Furthermore, only a
few studies have compared differences between genders in
this age population.
We found that most of the elderly who use drugs are
female. Although it is known that women both consult a
physician more frequently and participate more often in
research studies, data from the Brazilian Institute of
Geography and Statistics show that female residents in
Porto Alegre outnumber male residents.9,16 Previous studies
conducted in Porto Alegre, Brazil, using the elderly
population have shown that the elderly use around 3.2
drugs per day and that females uses more drugs.8,16
As reported by Flores and Mengue,16 the average number
of medications can be higher because people do not
commonly consider some agents to be drugs, such as
therapies for obesity, allergy, pain, diarrhea, disorders of the
kidney or bladder or digestive tract, as well nutritional
(vitamins and mineral) supplements.
Table 1 - Drug use and intensity of interaction in the elderly, according to gender and age group (N=438).
VARIABLE TOTAL AGE GROUP
,80 $80 p-value
DRUG USE [N(%)]
Men 102 (75.6) 86 (72.9) 16 (94.1) 0.057**
Women 274 (90.4) 239 (90.9) 35 (87.5) 0.499**
p** ,0,001 ,0,001 0,657
Total 376 (85.8) 325 (85.3) 51 (89.5) 0.399**
NUMBER OF MEDICATIONS (m¡sd)
Men 2.50¡2.33 2.20¡2.02 4.53¡3.26 0.010*
Women 3.51¡2.67 3.58¡2.74 3.03¡2.12 0.219*
p* ,0.001 ,0.001 0.094
Total 3.20¡2.61 3.15¡2.61 3.47¡2.58 0.390*
NUMBER OF DRUG ACTIVE PRINCIPLES (m¡sd)
Men 2.65¡2.59 2.33¡2.25 4.88¡3.64 0.012*
Women 3.88¡2.99 3.97¡3.07 3.35¡2.36 0.225*
p* ,0.001 ,0.001 0.124
Total 3.50¡2.92 3.46¡2.93 3.81¡2.86 0.403*
NUMBER OF INTERACTIONS (m¡sd)
Men 0.87¡1.89 0.71¡1.50 2.00¡3.46 0.149*
Women 1.33¡2.36 1.42¡2.49 0.73¡0.93 0.001*
p* 0.048 0.001 0.153
Total 1.19¡2.23 1.20¡2.25 1.11¡2.09 0.760*
INTENSITY OF INTERACTION [N(%)]
Men
Low 4 (9.1) 3 (8.6) 1 (11.1) 0.955**
Moderate 31 (70.5) 25 (71.4) 6 (66.7)
Severe 9 (20.5) 7 (20.0) 2 (22.2)
Women
Low 13 (8.7) 9 (7.0) 4 (20.0) 0.157**
Moderate 104 (69.8) 92 (71.3) 12 (60.0)
Severe 32 (21.5) 28 (21.7) 4 (20.0)
p** 0.988 0.936 0.842
Total
Low 17 (8.8) 12 (7.3) 5 (17.2) 0.216**
Moderate 135 (69.9) 117 (71.3) 18 (62.1)
Severe 41 (21.2) 35 (21.3) 6 (20.7)
(m¡sd): mean ¡ standard deviation.
*p-values were based on Student’s T-test;
**p-values were based on Pearson’s Chi-Square test.
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Surprisingly, after their eighties, men seem to take more
drugs and drug active principles. Similarly, in this study,
we found that women used more drugs than men only until
the age of 79. Women are more concerned with their health
and consult health services more often and earlier than men,
and women are more accustomed to the use of drugs. In
addition, more health programs are developed for women,
such as colon and breast cancer prevention programs.17
Furthermore, women more easily adopt the sick role; they
tend to recognize and experience more health problems,
more underlying gender-related psycho-social and beha-
vioral influences, and to perceive more symptoms than
men.18,19 These factors could explain the greater use of
medications by women and therefore the higher number of
DDI in among women younger than 79 years old. These
attitudes also provides to this group better medical
monitoring and treatment of disease and early diagnosis.
For some time, geriatricians have preferred to minimize
the number of drugs they prescribe to elderly patients to
prevent side effects and interactions.20 This medical
management could explain the decreased use of drugs
among the over-80 population, especially because recent
studies have shown that inappropriate prescriptions is a
great risk factor for adverse drug events and interactions in
the elderly population.21,22 Otherwise, men generally visit
doctors later than women, after their disease process has
already begun or when the symptoms have already
presented.19 It is important to highlight the fact that, in
the south of Brazil, the life expectancy is around 81 years
old,7 and this fate can explain why men start to visit doctors
later in their life.23
Similarly to other studies, our results show that the
majority of the elderly patients in this study used
cardiovascular system drugs, central nervous system drugs,
and anti-inflammatory agents.8,16 The majority of interac-
tions was of moderate intensity and also involved cardio-
vascular system drugs and NSAIDs. In fact, there are DDI
studies in the literature, but there is little agreement among
them with respect to the severity and clinical importance of
interactions.24
According to Schroeter et al.,25 the majority of the elderly
use the following combinations of cardiovascular drugs: a
diuretic and a b-adrenergic blocker, or a diuretic, a b-
adrenergic blocker, and an angiotensin-converting enzyme
inhibitor (ACE). Even though diuretics are widely recom-
mended by the World Health Organization (WHO)26 to
optimize therapeutic effects and diminish adverse events,
loop and thiazide diuretics largely contribute to moderate-
severity interactions, mainly when they are used with
captopril, propranolol and aspirin.
These associations might result in pharmacodynamic
interactions, leading to a loss of drug efficacy. For example,
the use of NSAIDs in patients receiving antihypertensive
therapy with b-adrenoceptor antagonists (b-blockers), thia-
zides, or ACE inhibitors can result in a loss of antihyper-
tensive action.27 In the elderly, pharmacodynamic interactions
are of particular relevance because they can reduce homeo-
static mechanisms, and the elderly are therefore particularly
Table 2 - The 30 most frequent Drug-Drug Interactions (DDI) in the elderly.
Interaction Intensity* N (%) Possible Effects
Verapamil - Sinvastatin Severe 10 (1.7) Increased risk of myopathy or rhabdomyolysis
Digoxin - Spironolactone Severe 5 (0.9) Digoxin toxicity (nausea, vomiting, cardiac arrhythmias)
Captopril - Aspirin Moderate 33 (5.7) Decreased captopril effectiveness
Enalapril - Thiazide Diuretics Moderate 30 (5.2) Postural hypotension (first dose)
Captopril - Thiazide Diuretics Moderate 25 (4.3) Postural hypotension (first dose)
Propranolol - Hydrochlorothiazide Moderate 25 (4.3) Hyperglycemia, hypertriglyceridemia
Aspirin - Enalapril Moderate 23 (3.9) Decreased effectiveness of enalapril
Aspirin - Furosemide Moderate 19 (3.3) Blunting of the diuretic effect of furosemide
Enalapril - Metformin Moderate 14 (2.4) Hyperkalemic lactic acidosis
Aspirin - Verapamil Moderate 14 (2.4) Increased risk of bleeding
Aspirin - Aluminum, Calcium or Magnesium
Containing Products
Moderate 12 (2.1) Decreased salicylate effectiveness
Diclofenac - Hydrochlorothiazide Moderate 9 (1.6) Decreased diuretic and antihypertensive efficacy
Furosemide - Digoxin Moderate 9 (1.6) Digoxin toxicity (nausea, vomiting, cardiac arrhythmias)
Captopril - Furosemide Moderate 9 (1.6) Postural hypotension (first dose)
Captopril – Ibuprofen Moderate 8 (1.4) Decreased antihypertensive and natriuretic effects
Ibuprofen - Hydrochlorothiazide Moderate 8 (1.4) Decreased diuretic and antihypertensive efficacy
Enalapril - Furosemide Moderate 8 (1.4) Postural hypotension (first dose)
Aspirin - Ibuprofen Moderate 8 (1.4) Decreased antiplatelet effect of aspirin
Diclofenac - Captopril Moderate 6 (1.0) Decreased antihypertensive and natriuretic effects
Glibenclamide - Hydrochlorothiazide Moderate 6 (1.0) Decreased glyburide effectiveness
Levothiroxine - Sinvastatine Moderate 6 (1.0) Decreased levothyroxine efficacy
Aspirin - Spironolactone Moderate 6 (1.0) Decreased spironolactone effectiveness
Aspirin - Diclofenac Moderate 6 (1.0) Reduced diclofenac efficacy
Propranolol - Nifedipine Moderate 6 (1.0) Hypotension and/or bradycardia.
Fluoxetine - Aspirin Moderate 6 (1.0) Increased risk of bleeding.
Metformin - Propranolol Moderate 5 (0.9) Hypoglycemia, hyperglycemia, or hypertension
Aspirin - Glibenclamide Moderate 5 (0.9) Increased risk for hypoglycemia
Propranolol - Furosemide Moderate 5 (0.9) Hypotension, bradycardia
Alendronate - Calcium (Ca Co3) Low 13 (2.3) Reduced alendronate absorption
Ibuprofen - Propranolol Low 7 (1.2) Decreased antihypertensive effect
*Intensity Low: risk of adverse outcomes appears small; Intensity Moderate: to avoid administration unless it is determined that the benefit of co-
administration outweighs the risk to the elderly; Intensity Severe: to avoid administration of combination.
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sensitive to combined postural hypotensive or sedative effects
of drugs.
In the case of aspirin, an NSAID, many interactions can
occur when it is combined with other drugs. In most of
them, aspirin leads to a decrease in the effectiveness of other
drugs, which might result in an increase in the dosage
prescribed. Otherwise, aspirin might increase the effect (or
side effect) of other drugs. In both cases, co-administration
with aspirin might increase the number of adverse events,
which can be confused with the severity of comorbidities.
The consequences of such interactions include a longer
duration of hospital stays with administration of more
drugs to patients, resulting in a higher probability of DDI.28
Another combination frequently used is digoxin and
furosemide, as reported by Moura et al.29 While in our
results this pair of drugs does not represent the most
frequent interaction, it is responsible for moderate-intensity
interactions that might precipitate or contribute to the
development of arrhythmias, especially in patients with pre-
existing cardiac abnormalities. These effects can be pre-
vented by dietary sodium restriction or by addition of
potassium-sparing diuretics.30
We also observed in our results a few severe interactions
that mainly involving the following drug combinations:
verapamil and sinvastatin that are both CYP3A4 inhibitors,
and their co-prescription might result in an increase in the
bioavailability of the statin, with a greater risk of myopathy
or rhabdomyolysis, as was well-documented by Molden et
al.31 and Jacobson;32 digoxin and spironolactone due to this
last drug reduces renal clearance and increases serum
concentration of digoxin, thus its dose should be reduced in
cases of combination with spironolactone.33
Although we could not evaluate real side effects, the
computer program used in this study provided information
about the associated clinical consequences or adverse
reactions to drugs and characterized the interactions
mechanisms. The same methodology has been previously
used by others.12,34,35
In the last several decades, polypharmacy among the
elderly has increased due to several reasons such as the
increase of life expectancy, the prevalence of non-degen-
erative chronic diseases with complex pharmacotherapeutic
regimens,14 the introduction of new drugs to the pharma-
ceutical market, self-medication including herbal drugs,
misuse of medication, poor quality of doctors’ choices of
prescriptions, doctors’ over-prescription of drugs, addi-
tional medicines prescribed to treat side effects, and poor
doctor-patient relationships.3,15
Physiological changes related to age can lead to pharma-
cokinetic and pharmacodynamic changes in elderly
patients, and these changes seem to be more serious among
women.7 Furthermore, women take more medicines and
self-report worse health than men. Older women who have
more income use more prescribed drugs.36 As Wortman et
al.37 reported, in the city of Porto Alegre, Brazil, the use of
benzodiazepines is higher among older and widowed or
divorced women. It is important to emphasize that female
life expectancy is about 7.62 years higher than that of males
in Brazil.23
In this study, we found that until 79 years of age, women
had more interactions than men in the same age group,
probably because women also use higher numbers of drugs
until this age. Thereafter, it is possible that women self-
medicate more often and that they do not consider several
kinds of medications to be drugs.16 Female patients have a
greater risk of developing adverse drug reactions than
males due to multiple pharmacokinetic parameters, such as
a lower rate of drug absorption, reduced hepatic clearance, a
greater percentage of body fat with age that can increase
distribution volumes for lipophilic drugs, and higher oral
bioavailability.7 In the same way, gastric acid secretion,
gastrointestinal and renal blood flow, and immunological
differences, are several factors that might contribute to sex-
related differences in pharmacokinetics.38
Greater body mass in men results in alterations of the
distribution volume and total clearance of most medica-
tions. Besides, gender differences in oxidative metabolism,
conjugation, and renal filtration; secretion, and reabsorption
lead to faster drug clearance in men compared with
women.38
There are also pharmacodynamic differences between
men and women, particularly for cardiac and psychotropic
medications. For instance, various antipsychotics appear
more effective in women than men for the same dosage and
plasma concentration. Furthermore, women are at increased
risk for half-life prolongation with certain anti-arrhythmic
drugs compared with men, even at equivalent serum
concentrations.7
In order to prevent DDI or diminish its consequences,
several measures should be considered for elderly patients,
including periodic review of their medicines and their
adverse events, preference for monotherapy as soon as
possible instead of associations containing fixed dosages,
choice of drugs with proven efficacy, and suspension of
drug use as soon as possible. Therefore, the comprehen-
siveness of the prescriptions and the pharmacologic
orientations beyond simply the regimen should be eval-
uated.39
For reducing drug-drug and food-drug interactions, it
might also be important to change the administration
schedule for elderly patients at risk for nutritional defi-
ciency.6 This practice aims to diminish potential adverse
drug reactions and prevent aggravation of the clinical
features that occurs due to the great number of drugs
utilized by each elderly individual.
The present study demonstrates that potential drug
interactions in the elderly correlate with the concomitant
use of multiple drugs. Furthermore, elderly patients should
be closely monitored for adverse drug reactions and
potential pharmacological interactions, particularly with
drugs that target the cardiovascular system, given our
finding that they were the most commonly used class of
drug and the most frequently involved in drug interactions.
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